Goldman Sachs lifts Nasdaq price target to $120 and keeps Buy rating
Goldman Sachs raised its Nasdaq price target to $120 from $109 and kept its Buy rating. Source: Dow Jones Newswires.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Goldman Sachs analysts raised their price target on Nasdaq (NDAQ) shares to $120 from $109. The bank kept its Buy rating on the stock. Dow Jones Newswires, citing Benzinga, reported the change at 18:13 GMT on October 23, 2026.
Target revisions like this come out regularly and usually have little effect on the broader market. For investors, they mainly show how a major bank assesses the company's outlook.
why it matters
Exchange operators depend on trading volumes, listings and market data sales, so analyst views on such companies are often read alongside activity in equity markets. A single target change does not alter the fundamental picture and is not a forecast of share price moves.
tags
instruments
sources
- Nasdaq Price Target Raised to $120.00/Share From $109.00 by Goldman Sachs — Dow Jones Newswires, 23 October 2026 at 18:13 UTC
- AbbVie Price Target Raised to $294.00/Share From $258.00 by Goldman Sachs — Dow Jones Newswires, 23 October 2026 at 18:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗